HomeInsightsStock Comparison

Bafna Pharmaceuticals Ltd vs Medico Intercontinental Ltd Stock Comparison

Bafna Pharmaceuticals Ltd vs Medico Intercontinental Ltd Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

  • The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 131.85 as of 05 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Medico Intercontinental Ltd changed from 3.2 on March 2021 to 7 on March 2025 . This represents a CAGR of 16.95% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Medico Intercontinental Ltd changed from ₹ 8.33 crore on March 2021 to ₹ 35.47 crore on March 2025 . This represents a CAGR of 33.61% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Medico Intercontinental Ltd for the Dec '25 is ₹ 20.19 crore as compare to the Sep '25 revenue of ₹ 20.95 crore. This represent the decline of -3.63% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Medico Intercontinental Ltd for the Dec '25 is ₹ 1.93 crore as compare to the Sep '25 ebitda of ₹ -0.33 crore. This represent the decline of -684% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Medico Intercontinental Ltd changed from ₹ 1.08 crore to ₹ -1.68 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Medico Intercontinental Ltd changed from 5.88 % on March 2023 to 0 % on March 2025 . This represents a CAGR of -100.00% over 3 years .

About Bafna Pharmaceuticals Ltd

  • Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
  • The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
  • Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
  • During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Medico Intercontinental Ltd

  • Medico Intercontinental Limited, formerly known as Intercontinental Leasing & Finance Company Limited was incorporated on August 14, 1984 in Ahmedabad, India.
  • The Company changed its name to 'Medico Intercontinental Limited' in December, 2018.
  • The Company is involved in trading of pharmaceutical products. The Company is also providing a platform to all research based bio-pharmaceutical companies reaching their novel and innovative therapies to every part of the globe.
  • From helping people obtain their medications to using cutting-edge scientific technology to discover new treatments, Medico's entrepreneurial spirit, teamwork-oriented culture and commitment to rare diseases create a unique platform for transforming patient outcomes.
  • The Company's commitment to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first across the continents.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Medico Intercontinental Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Medico Intercontinental Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 311 Cr while Market cap of Medico Intercontinental Ltd is 23 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Medico Intercontinental Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Medico Intercontinental Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Medico Intercontinental Ltd?

As of May 5, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹131.85. On the other hand, Medico Intercontinental Ltd stock price is INR ₹23.29.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Medico Intercontinental Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Medico Intercontinental Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions